Impact of the COVID-19 Pandemic on Chronic Neurological Disorders: Focus on Patients with Dementia.
COVID-19
alzheimer’s disease
dementia
multiple sclerosis
neurological disorders
parkinson’s disease
Journal
CNS & neurological disorders drug targets
ISSN: 1996-3181
Titre abrégé: CNS Neurol Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269155
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
08
2021
revised:
13
10
2021
accepted:
28
10
2021
pubmed:
14
1
2022
medline:
9
9
2022
entrez:
13
1
2022
Statut:
ppublish
Résumé
The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) represents a public health problem worldwide. COVID-19 triggers a maladaptive cytokine release commonly referred to as cytokine storm syndrome with increased production of proinflammatory cytokines, which also appears to contribute to chronic neuroinflammation and neurodegenerative disorders' appearance, including multiple sclerosis, Parkinson's disease, and Alzheimer's disease. In this context, SARS-CoV-2 might enter the central nervous system through binding with the angiotensin converting enzyme 2 receptors which are highly expressed in glial cells and neurons. For this reason, an association between COVID-19, its dependent cytokine storm, and the development and/or progression of neurodegenerative disorders might be evaluated. Therefore, the aim of this review was to assess the impact of COVID-19 on neurodegenerative disorders, focusing on the possible increased mortality risk and/or deterioration of the clinical course of pre-existing chronic neurological diseases in patients with dementia.
Identifiants
pubmed: 35021982
pii: CNSNDDT-EPUB-120099
doi: 10.2174/1871527321666220111124928
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1017-1026Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.